Xenetic Financial Statements From 2010 to 2025

XBIO Stock  USD 3.99  0.04  0.99%   
Xenetic Biosciences financial statements provide useful quarterly and yearly information to potential Xenetic Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Xenetic Biosciences financial statements helps investors assess Xenetic Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Xenetic Biosciences' valuation are summarized below:
Gross Profit
2.5 M
Profit Margin
(1.62)
Market Capitalization
6.1 M
Enterprise Value Revenue
0.0159
Revenue
2.5 M
We have found one hundred twenty available fundamental gauges for Xenetic Biosciences, which can be analyzed and compared to other ratios and to its peers. Self-guided Investors are advised to confirm Xenetic Biosciences' prevalent fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 26th of February 2025, Market Cap is likely to grow to about 9.5 M, though Enterprise Value is likely to grow to (4.1 M).

Xenetic Biosciences Total Revenue

1.63 Million

Check Xenetic Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xenetic Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 180.9 K, Selling General Administrative of 3.8 M or Total Revenue of 1.6 M, as well as many indicators such as Price To Sales Ratio of 1.77, Dividend Yield of 0.0 or PTB Ratio of 1.19. Xenetic financial statements analysis is a perfect complement when working with Xenetic Biosciences Valuation or Volatility modules.
  
Check out the analysis of Xenetic Biosciences Correlation against competitors.
To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.

Xenetic Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets18 M12.2 M15.2 M
Pretty Stable
Short and Long Term Debt Total23.1 K24.3 K178.2 K
Slightly volatile
Other Current Liabilities997.5 K654.1 K840.1 K
Very volatile
Total Current Liabilities692.2 K728.6 K1.7 M
Pretty Stable
Total Stockholder Equity13.7 M11.3 M11.7 M
Slightly volatile
Accounts Payable205.9 K216.7 K563.6 K
Pretty Stable
Cash7.7 M10.3 M6.8 M
Slightly volatile
Non Current Assets Total870.7 K916.5 K6.9 M
Slightly volatile
Cash And Short Term Investments7.7 M10.3 M6.8 M
Slightly volatile
Common Stock Total Equity7.5 K7.9 K119.7 K
Pretty Stable
Liabilities And Stockholders Equity18 M12.2 M15.2 M
Pretty Stable
Total Liabilities692.2 K728.6 K3.3 M
Slightly volatile
Property Plant And Equipment Gross79.8 K45.2 K79.9 K
Slightly volatile
Total Current Assets8.9 M11 M7.8 M
Slightly volatile
Common Stock1.3 K1.4 K273 K
Slightly volatile
Non Currrent Assets Other697.2 K1.2 M616.2 K
Slightly volatile
Net Receivables898.5 K575 K748.9 K
Very volatile
Common Stock Shares Outstanding1.8 M1.8 M549.8 K
Slightly volatile
Other Current Assets617.8 K543.4 K676.2 K
Very volatile
Other Stockholder Equity162.6 M233.2 M144.2 M
Slightly volatile
Accumulated Other Comprehensive Income311.7 K228.4 K440.4 K
Slightly volatile
Short Term Debt23.1 K24.3 K235.3 K
Slightly volatile
Intangible Assets7.6 M8.3 M9.3 M
Slightly volatile
Capital Surpluse157.1 M223.3 M145.4 M
Slightly volatile
Deferred Long Term Liabilities23.1 K24.3 K1.9 M
Slightly volatile
Property Plant Equipment43.7 K24.3 K65.3 K
Slightly volatile
Other Liabilities23.1 K24.3 K942.9 K
Very volatile
Other Assets679.4 K1.3 M616.2 K
Slightly volatile
Short Term Investments73.4 K77 K67.7 K
Slightly volatile
Short and Long Term Debt2.4 M4.7 M2.8 M
Slightly volatile
Non Current Liabilities Other28.4 K24.3 K36.4 K
Slightly volatile
Preferred Stock Total Equity2.3 K2.5 K2.8 K
Slightly volatile
Net Invested Capital10.9 M8.8 M13.5 M
Slightly volatile
Capital Stock2.9 KK11 K
Slightly volatile

Xenetic Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense180.9 K190.4 K1.3 M
Pretty Stable
Selling General Administrative3.8 M3.2 MM
Pretty Stable
Other Operating Expenses9.6 M6.4 M10.7 M
Very volatile
Research Development5.6 M3.1 MM
Very volatile
Total Operating Expenses9.6 M6.4 M10.7 M
Very volatile
Interest Income424.8 K404.6 K106.3 K
Slightly volatile
Preferred Stock And Other Adjustments4.2 M4.8 M5.2 M
Slightly volatile
Non Recurring6.9 M10.6 M5.5 M
Slightly volatile

Xenetic Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation242 K254.8 K886.3 K
Pretty Stable
Begin Period Cash Flow9.1 M15.1 M9.9 M
Very volatile
End Period Cash Flow8.3 M10.3 M8.3 M
Pretty Stable
Change To Netincome350.9 K369.4 K4.7 M
Very volatile
Dividends Paid31.6 M35.5 M38.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.771.8736.6027
Very volatile
PTB Ratio1.190.620.9368
Very volatile
Days Sales Outstanding193328316
Slightly volatile
Book Value Per Share7.07.371.6 K
Slightly volatile
Average Payables569.5 K839.4 K764.5 K
Slightly volatile
Stock Based Compensation To Revenue0.120.136.7733
Very volatile
Capex To Depreciation17.4716.649.4885
Slightly volatile
PB Ratio1.190.620.9368
Very volatile
Days Of Inventory On Hand0.0080.0090.0098
Slightly volatile
Payables Turnover0.120.110.135
Slightly volatile
Sales General And Administrative To Revenue1.531.6138.8473
Very volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue1.51.5840.8827
Very volatile
Capex To Revenue0.180.340.2315
Very volatile
Cash Per Share6.426.76811
Slightly volatile
Days Payables Outstanding4.2 K4.5 KK
Pretty Stable
Intangibles To Total Assets0.740.490.5865
Slightly volatile
Current Ratio11.1910.666.8572
Slightly volatile
Receivables Turnover2.113.523.2967
Slightly volatile
Graham Number21.5822.724.8 K
Slightly volatile
Shareholders Equity Per Share7.07.371.6 K
Slightly volatile
Debt To Equity0.00160.00177.5505
Slightly volatile
Capex Per Share0.380.410.0007
Slightly volatile
Average Receivables63.2 K66.6 K102.8 K
Slightly volatile
Revenue Per Share1.821.9155.0345
Slightly volatile
Interest Debt Per Share0.02870.030362.3029
Slightly volatile
Debt To Assets0.00150.00160.0693
Slightly volatile
Operating Cycle193329316
Slightly volatile
Price Book Value Ratio1.190.620.9368
Very volatile
Days Of Payables Outstanding4.2 K4.5 KK
Pretty Stable
Company Equity Multiplier1.181.259.1409
Slightly volatile
Long Term Debt To Capitalization0.01110.01170.0716
Slightly volatile
Total Debt To Capitalization0.00160.00170.076
Slightly volatile
Debt Equity Ratio0.00160.00177.5505
Slightly volatile
Quick Ratio11.1910.666.8572
Slightly volatile
Net Income Per E B T1.11.121.1516
Slightly volatile
Cash Ratio10.499.996.3183
Slightly volatile
Days Of Inventory Outstanding0.0080.0090.0098
Slightly volatile
Days Of Sales Outstanding196107133
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.821.01.0339
Very volatile
Price To Book Ratio1.190.620.9368
Very volatile
Fixed Asset Turnover13.8114.5439.7913
Very volatile
Debt Ratio0.00150.00160.0693
Slightly volatile
Price Sales Ratio1.771.8736.6027
Very volatile
Asset Turnover0.230.220.1131
Slightly volatile
Gross Profit Margin0.770.890.9364
Very volatile
Price Fair Value1.190.620.9368
Very volatile

Xenetic Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap9.5 M6.1 M11.5 M
Slightly volatile

Xenetic Fundamental Market Drivers

Cash And Short Term InvestmentsM

Xenetic Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Xenetic Biosciences Financial Statements

Xenetic Biosciences investors utilize fundamental indicators, such as revenue or net income, to predict how Xenetic Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-24.3 K-23.1 K
Total Revenue2.9 M1.6 M
Cost Of Revenue31.1 K29.5 K
Stock Based Compensation To Revenue 0.13  0.12 
Sales General And Administrative To Revenue 1.61  1.53 
Research And Ddevelopement To Revenue 1.58  1.50 
Capex To Revenue 0.34  0.18 
Revenue Per Share 1.91  1.82 
Ebit Per Revenue(1.60)(1.68)

Pair Trading with Xenetic Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xenetic Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xenetic Biosciences will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Xenetic Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xenetic Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xenetic Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xenetic Biosciences to buy it.
The correlation of Xenetic Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xenetic Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xenetic Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xenetic Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Xenetic Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Xenetic Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xenetic Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xenetic Biosciences Stock:
Check out the analysis of Xenetic Biosciences Correlation against competitors.
To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.66)
Revenue Per Share
1.638
Quarterly Revenue Growth
0.005
Return On Assets
(0.27)
Return On Equity
(0.45)
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.